The global human combination vaccines market size was valued at USD 10.80 billion in 2024 and is expected to reach USD 21.36 billion by 2032, at a CAGR of 8.90% during the forecast period
The market growth is largely fueled by the increasing prevalence of infectious diseases, rising pediatric population, and growing adoption of combination vaccines that reduce the number of injections while ensuring broader immunization coverage
Furthermore, advancements in vaccine technologies, strong government immunization programs, and increasing awareness about preventive healthcare are driving the demand for human combination vaccines across all age groups, establishing them as a preferred choice in modern healthcare, thereby significantly boosting the industry’s growth